MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases

Core Viewpoint - MaxCyte and Kamau Therapeutics have entered into a strategic platform license agreement, allowing Kamau to utilize MaxCyte's Flow Electroporation technology and ExPERT platform for research, clinical, and commercial purposes, while MaxCyte will receive licensing fees and program-related revenue [1][2]. Company Overview - MaxCyte is a cell-engineering company focused on advancing cell-based therapeutics and bioprocessing applications, with over 20 years of experience in developing enabling platform technologies [5]. - Kamau Therapeutics is a clinical-stage gene correction company that aims to develop therapies for serious genetic diseases, utilizing high-efficiency targeted gene integration based on homology-directed repair (HDR) technology [3][6]. Agreement Details - The agreement grants Kamau non-exclusive rights to MaxCyte's technologies, which will help optimize Kamau's clinical manufacturing process and expedite the development of its lead product candidate for sickle cell disease (SCD) [2][4]. - MaxCyte's ExPERT platform is designed for complex and scalable cell engineering, providing high transfection efficiency and enhanced functionality essential for next-generation biological therapeutics [4]. Product Development - Kamau's lead investigational program, nulacel, is in clinical development for sickle cell disease and aims to correct the mutation in the beta-globin gene, restoring normal hemoglobin levels in patients [3][7]. - The collaboration with MaxCyte is expected to enhance Kamau's capabilities in delivering curative therapies for genetic diseases with unmet medical needs [4][6].